ESMO Asia 2016 Congress

Oncology Meeting Resources

16 Dec - 19 Dec 2016, Singapore

ESMO Asia 2016 Square

The ESMO Asia Congress comprised both scientific and educational tracks prepared by an international scientific committee. There was a strong emphasis on state of the art science, including a call for abstracts, and the current standard of care across all major tumour types.

Abstracts, presentations and webcasts from the ESMO Asia 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links

Format available

BackgroundMedian overall survival (OS) for first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC) with sorafenib (sor) is up to 11 mo and 7–8 mo with best supportive care (BSC) post-sor failure.

Date: 19 Dec 2016
Presenter: Ignacio Melero
Resources: Abstract
Topics: Hepatobiliary Cancers, Immunotherapy

BackgroundClaudin(CLDN)18.2 is a stomach specific tight junction protein. The chimeric monoclonal anti-CLDN18.2 antibody IMAB362 potently activates complement and antibody dependent cellular cytotoxicity.

Date: 19 Dec 2016
Presenter: Florian Lordick
Resources: Abstract
Topics: Clinical Research, Gastric Cancer